Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. Amendment No. 5 to...PTC Therapeutics, Inc. • August 3rd, 2023 • Pharmaceutical preparations
This Amendment No. 5 (the “5th Amendment”) dated April 28, 2023 amends the License Agreement dated February 8, 2016 (the “Original Agreement”), as amended by Amendment No. 1 to the License Agreement dated July 31, 2017 (the “1st Amendment”) as further amended by Amendment No. 2 to the License Agreement dated May 28, 2019 (the “2nd Amendment”) as further amended by Amendment No. 3 to the License Agreement dated January 8, 2020 (the “3rd Amendment” and as further amended by Amendment No. 4 to the License Agreement dated April 9, 2020 (the 4th Amendment”), (together and collectively with the Original Agreement (the “Agreement”) by and between Shiratori Pharmaceutical Co. Ltd. having a principal place of business at WBG Marive East 28F, 2-6-1 Nakese, Mihama-ku, Chiba-shi, Chiba JAPAN (“Shiratori”) and Censa Pharmaceutical Inc., having a principal place of business at 65 Willian Street, Suite 200, Wellesley, MA 02481 (“Censa”).
